114 related articles for article (PubMed ID: 8612724)
1. Nuclear accumulation of MDM2 protein in well-differentiated papillary thyroid carcinomas.
Jennings T; Bratslavsky G; Gerasimov G; Troshina K; Bronstein M; Dedov I; Alexandrova G; Figge J
Exp Mol Pathol; 1995 Jun; 62(3):199-206. PubMed ID: 8612724
[TBL] [Abstract][Full Text] [Related]
2. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features.
Horie S; Maeta H; Endo K; Ueta T; Takashima K; Terada T
Pathol Int; 2001 Jan; 51(1):11-5. PubMed ID: 11148457
[TBL] [Abstract][Full Text] [Related]
4. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
5. Nuclear p53 immunoreactivity in papillary thyroid cancers is associated with two established indicators of poor prognosis.
Gerasimov G; Bronstein M; Troshina K; Alexandrova G; Dedov I; Jennings T; Kallakury BV; Izquierdo R; Boguniewicz A; Figge H
Exp Mol Pathol; 1995 Feb; 62(1):52-62. PubMed ID: 7556591
[TBL] [Abstract][Full Text] [Related]
6. p53, MDM2, bcl-2 staining in follicular neoplasms of the thyroid gland.
Czyz W; Kuzdak K; Pasieka Z; Timler D; Brzeziński J
Folia Histochem Cytobiol; 2001; 39 Suppl 2():167-8. PubMed ID: 11820589
[TBL] [Abstract][Full Text] [Related]
7. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland.
Holm R; Nesland JM
J Pathol; 1994 Mar; 172(3):267-72. PubMed ID: 8195930
[TBL] [Abstract][Full Text] [Related]
8. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas.
Haugen DR; Akslen LA; Varhaug JE; Lillehaug JR
Cancer Res; 1996 Mar; 56(6):1184-8. PubMed ID: 8640794
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of p53 in differentiated, poorly differentiated and undifferentiated carcinomas of the thyroid.
Soares P; Cameselle-Teijeiro J; Sobrinho-Simões M
Histopathology; 1994 Mar; 24(3):205-10. PubMed ID: 8200621
[TBL] [Abstract][Full Text] [Related]
11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
12. The expression of the MDM2 gene, a p53 binding protein, in thyroid carcinogenesis.
Zou M; Shi Y; al-Sedairy S; Hussain SS; Farid NR
Cancer; 1995 Jul; 76(2):314-8. PubMed ID: 8625108
[TBL] [Abstract][Full Text] [Related]
13. Intercellular adhesion molecule-1 (ICAM-1) immunoreactivity in well-differentiated thyroid papillary carcinomas.
Tanda F; Cossu A; Bosincu L; Manca A; Ibba M; Massarelli G
Mod Pathol; 1996 Jan; 9(1):53-6. PubMed ID: 8821957
[TBL] [Abstract][Full Text] [Related]
14. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
15. Studies on expression of p14ARF and MDM2 in human thyroid neoplasms.
Qi XW; Wu HR; Yin Y; Xia SH; Feng JJ; Pu Y; Jin LF
Panminerva Med; 2015 Mar; 57(1):43-7. PubMed ID: 25386766
[TBL] [Abstract][Full Text] [Related]
16. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
17. Expression of the cell death-inducing gene bax in carcinomas developed from the follicular cells of the thyroid gland.
Branet F; Brousset P; Krajewski S; Schlaifer D; Selves J; Reed JC; Caron P
J Clin Endocrinol Metab; 1996 Jul; 81(7):2726-30. PubMed ID: 8675602
[TBL] [Abstract][Full Text] [Related]
18. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis.
Girod SC; Cesarz D; Fischer U; Krueger GR
Anticancer Res; 1995; 15(4):1453-7. PubMed ID: 7654034
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas.
Harlozińska A; Bar J; Montenarh M
Anticancer Res; 2000; 20(2A):1049-56. PubMed ID: 10810396
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.
Nikiforova MN; Kimura ET; Gandhi M; Biddinger PW; Knauf JA; Basolo F; Zhu Z; Giannini R; Salvatore G; Fusco A; Santoro M; Fagin JA; Nikiforov YE
J Clin Endocrinol Metab; 2003 Nov; 88(11):5399-404. PubMed ID: 14602780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
